Conformal Radiotherapy in Patients with Prostate Cancer A Three-Year Study at the National Cancer Institute of Colombia

Authors

  • Rosalba Ospino Peña Instituto Nacional de Cancerología
  • Ilse Vásquez Aponte Instituto Nacional de Cancerología
  • Ricardo Cendales Instituto Nacional de Cancerología
  • Franz Usuga Instituto Nacional de Cancerología

Keywords:

Prostate neoplasia, conformal radiotherapy
Abstract Authors References How to Cite

Abstract

Objective: To describe clinical and demographic characteristics, event free survival, and the toxicity in prostate cancer patients treated with conformal radiotherapy at the National Cancer Institute of Colombia.
Methods: Case histories of patients treated with conformal radiotherapy between January, 2003 and December, 2006 were reviewed. Descriptive analyses were carried out and a survival analysis was performed with the Kaplan-Meier method.
Results: One hundred and ninety-six patients were treated, 114 of whom were included in the analyses. Median follow-up was 14.4 months. Disease free survival at month 30 was 74%. Six events occurred in the high risk group,three in the intermediate risk group, and none in the low risk group. Relapse free survival was 100%, 73% and 67% for the low, intermediate, and high risk groups, respectively. Non pre-existent chronic toxicity of any degree was: 12.8%, urinary; 10.8%, rectal; and 18.3%, sexual.
Conclusions: Follow-up was short and the possiblity of making comparisons with international series was limited. According to risk group, no statistically significant differences were shown for relapse free survival; however, events occurred in accordance with level of risk. A larger sample group could have enhanced the study´s potential to detect these differences. Rectal, sexual and urinary toxicities were not measured systematically, hence the results are not conclusive. Guidelines should be adopted for the application of hormonotherapy.

Author Biographies

Rosalba Ospino Peña, Instituto Nacional de Cancerología

Instituto Nacional de Cancerología, Bogotá, Colombia.

Ilse Vásquez Aponte, Instituto Nacional de Cancerología

Instituto Nacional de Cancerología, Bogotá, Colombia.
Pontificia Universidad Javeriana, Bogotá, Colombia.

Ricardo Cendales, Instituto Nacional de Cancerología

Instituto Nacional de Cancerología, Bogotá, Colombia.
Pontificia Universidad Javeriana, Bogotá, Colombia.

Franz Usuga, Instituto Nacional de Cancerología

Instituto Nacional de Cancerología, Bogotá, Colombia.
Pontificia Universidad Javeriana, Bogotá, Colombia.

References

Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5. version 2, Lyon, IARC Press, 2004.

Piñeros M, Ferlay J, Murillo R. Incidencia estimada y mortalidad por cáncer en Colombia. 1995 - 1999. Instituto Nacional de Cancerología, Internacional Agency for Research on Cancer y Ministerio de Protección Social. 2005. [Sitio en internet]. Bogotá: Instituto Nacional de Cancerología: 2005. Hallado en http://www.incancerologia.gov.co/documentos/3_20_2007_1_13_22_PM_libro1.pdf. Acceso el 30 de junio de 2008.

Murillo RH, Piñeros M, Pardo C, Quintero A. Anuario Estadístico 2006 "Por el control del cáncer". [Publicación Institucional en Internet]. Bogotá: Instituto Nacional de Cancerología: 2005. http://www.incancerologia.gov.co/documentos/1_3_2008_10_21_58_AM_anuario%20estadistico.pdf. Acceso el 20 de julio de 2008.

Zelefsky M, Valicenti R, Goodman Karin, Perez C. Part I Male genitourinary tumors. Chapter 58 Prostate cancer. In: Perez C. Principles and practice of radiation oncology. Fourth edition. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1698-1701.

Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet. 1999;53(9149):267-72.

https://doi.org/10.1016/S0140-6736(98)05180-0

Koper PC, Stroom JC, Van Putten WL, Korevaar GA, Heijmen BJ, Wijnmaalen A, et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):727-34.

https://doi.org/10.1016/S0360-3016(98)00406-4

Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007 Jun;8(6):475-87.

https://doi.org/10.1016/S1470-2045(07)70143-2

Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005 Sep 14;294(10):1233-9.

https://doi.org/10.1001/jama.294.10.1233

Peeters ST, Heemsbergen WD, Koper PC, Van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006 May 1;24(13):1990-6.

https://doi.org/10.1200/JCO.2005.05.2530

Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74.

https://doi.org/10.1016/j.ijrobp.2007.06.054

República de Colombia. Ministerio de Salud. Resolución 8430 de 1993 (4 de octubre), por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. Diario oficial No. 42.247, 9 de enero de 1996.

Consensus Statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1035-41.

https://doi.org/10.1016/S0360-3016(97)00002-3

Roach M 3rd, Hanks G, Thames H, Schellhammer P, Shipley W, Sokol G, et al: Defining biochemical failure following radiotherapy with or with out hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-974.

https://doi.org/10.1016/j.ijrobp.2006.04.029

Pavy J.J, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J, et al. Late Effects Toxicity Scoring: The Soma Scale. Int. J. Radiation Oncology Biol Phys. 1995 Mar 30;31(5):1043- 1047.

https://doi.org/10.1016/0360-3016(95)00059-8

Roach M 3rd, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):33-7.

https://doi.org/10.1016/0360-3016(94)90138-4

Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001 Dec;58(6):843-8.

https://doi.org/10.1016/S0090-4295(01)01441-8

Milano MT, Constine LS, Okunieff P. Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol. 2007 Apr;17(2):131-40.

https://doi.org/10.1016/j.semradonc.2006.11.009

Nilsson S, Norlén BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol. 2004;43(4):316-381. Review.

https://doi.org/10.1080/02841860410030661

Leborgne F, Leborgne JH, Zubizarreta B, Leborgne JD, Aguiar S, et al. Cáncer localizado de próstata: Experiencia de diez años con la radioterapia conformal tridimensional. Rev Med Uruguay. 2004;20(3):193-201.

Zelefsky M, Fuks Z, Chan H, Ling C, Hunt M, Leibel S. Ten-year results of dose escalation with 3-dimensional conformal radiotherapy for patients with clinically localized prostate cancer. Int J Rad Oncol Biol Phys 2003 Oct:57;(2) Suppl 1: S149-S150.

https://doi.org/10.1016/S0360-3016(03)00920-9

Madalinska JB, Essink-Bot ML, Koning HJ, Kirkels WJ, Van der Maas PJ, Schröder FH. Health-Related Quality-of-Life Effects of Radical Prostatectomy and Primary Radiotherapy for Screen-Detected or Clinically Diagnosed localized Prostate Cancer. J Clin Oncol. 2001;19:1619-1628.

https://doi.org/10.1200/JCO.2001.19.6.1619

Potosky Al, Davis WW, Hoffman RM, Stanford JL,. Stephenson RA, Penson DF, et al. Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study. Journal of the National Cancer Institute. 2004; 96:1358-67.

https://doi.org/10.1093/jnci/djh259

Kuban D, Pollack A, Huang E, Levy L, Dong L, Starkschall G, et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1260-8.

https://doi.org/10.1016/S0360-3016(03)00772-7

How to Cite

[1]
Ospino Peña, R. et al. 2009. Conformal Radiotherapy in Patients with Prostate Cancer A Three-Year Study at the National Cancer Institute of Colombia. Revista Colombiana de Cancerología. 13, 3 (Sep. 2009), 124–133.

Downloads

Download data is not yet available.

Downloads

Issue

Vol. 13 No. 3 (2009)

Section

Research/original articles

License

Todos los derechos reservados.